The Patent Finder
GB

Gasherbrum Bio, Inc.

First filing 2022
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Nine patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2041. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2041
Next term end
6
Patent families

When these terms end

Each bar runs from grant to computed term end. 2022 to 2044.
US 11,492,365 Heterocyclic GLP-1 Agonists Feb 5, 2041
US 11,926,643 Heterocyclic GLP-1 Agonists Feb 5, 2041
US 12,552,791 Heterocyclic GLP-1 Agonists Apr 28, 2041
US 11,897,851 Heterocyclic GLP-1 Agonists Aug 6, 2041
US 12,528,781 Heterocyclic GLP-1 Agonists Aug 6, 2041
US 12,221,442 Heterocyclic GLP-1 Agonists Aug 27, 2041
US 11,926,626 Heterocyclic GLP-1 Agonists Oct 7, 2041
US 12,595,264 Heterocyclic GLP-1 Agonists Oct 9, 2042
US 12,291,529 Heterocyclic GLP-1 Agonists Feb 9, 2044
20272032203720422044
16 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 13, 2027
    The maintenance fee for Heterocyclic GLP-1 Agonists (US 11,897,851) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
  • 2 fees due Sep 12, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,492,365Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 11,926,643Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 12,552,791Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 11,897,851Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 12,528,781Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 12,221,442Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 11,926,626Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 12,595,264Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
US 12,291,529Heterocyclic GLP-1 Agonists
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 16 applications pending · 5 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited